Shopping Cart
Remove All
Your shopping cart is currently empty
Brolucizumab (Synonyms: RTH258, ESBA 1008, DLX1008)
Catalog No. T80593 Copy Product Info
🥰Excellent
Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity (K D = 1.05 pM). through its potent blockade of vascular endothelial growth factor A (VEGF-A), Brolucizumab effectively reduces pathological neovascularization and vascular leakage within the macula and is under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Brolucizumab
Copy Product Info🥰Excellent
Catalog No. T80593
Synonyms RTH258, ESBA 1008, DLX1008
Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity (K D = 1.05 pM). through its potent blockade of vascular endothelial growth factor A (VEGF-A), Brolucizumab effectively reduces pathological neovascularization and vascular leakage within the macula and is under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Brolucizumab
Cas No. 1531589-13-5
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $813 | - | In Stock | |
| 5 mg | $2,270 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:≥95% (SDS-PAGE); 99.67% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity (K D = 1.05 pM). through its potent blockade of vascular endothelial growth factor A (VEGF-A), Brolucizumab effectively reduces pathological neovascularization and vascular leakage within the macula and is under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD). |
| In vitro | Brolucizumab (2683 nM) inhibits VEGFR1 phosphorylation in VEGF-A112-induced U87MG human glioma cells and VEGFR2 phosphorylation in ZHE-483-2 GMECs. [1] |
| In vivo | Brolucizumab (15 mg/kg, intravenous injection, five days a week) was used to treat mSLK-KSHV xenografts and the tumor growth in vivo was observed. Results: Brolucizumab slowed the growth of mSLK-KSHV xenograft tumors. [2] |
| Synonyms | RTH258, ESBA 1008, DLX1008 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | VEGFA |
| Molecular Weight | ~150 kDa |
| Cas No. | 1531589-13-5 |
| Isotype | scFv-kappa-heavy |
| Storage | Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Brolucizumab | purchase Brolucizumab | Brolucizumab cost | order Brolucizumab | Brolucizumab in vivo | Brolucizumab in vitro | Brolucizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.